Asthma remission: what is it and how can it be achieved?
暂无分享,去创建一个
[1] R. Chaudhuri,et al. Biologics in severe asthma: Which one, When and Where? , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[2] W. Carr,et al. Exacerbations in US Severe Asthma: Incidence, Characteristics, Predictors, and Effects of Biologic Treatments. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[3] J. Upham,et al. Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.
[4] M. Humbert,et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) , 2021, European Respiratory Journal.
[5] U. Walker,et al. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. , 2021, Rheumatology.
[6] C. Jenkins,et al. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. , 2021, The journal of allergy and clinical immunology. In practice.
[7] I. Pavord,et al. Dupilumab Treatment Leads to Clinical Asthma Remission in Patients With Uncontrolled Moderate-to-Severe Asthma With Type 2 Inflammation , 2021, Journal of Allergy and Clinical Immunology.
[8] Shih-Lung Cheng. Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways , 2021, Diagnostics.
[9] C. Ulrik,et al. Remission and changes in severity over 30 years in an adult asthma cohort. , 2020, The journal of allergy and clinical immunology. In practice.
[10] W. Busse,et al. How Do Asthma Biologics Relate to Remission for Asthma? , 2020, The journal of allergy and clinical immunology. In practice.
[11] A. Agustí,et al. TREATABLE TRAITS THAT PREDICT HEALTH STATUS AND TREATMENT RESPONSE IN AIRWAY DISEASE. , 2020, The journal of allergy and clinical immunology. In practice.
[12] A. Lindberg,et al. Remission of adult-onset asthma is rare: a 15-year follow-up study , 2020, ERJ Open Research.
[13] E. Israel,et al. A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER) , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[14] I. Dávila,et al. Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A consensus statement. , 2020, Journal of investigational allergology & clinical immunology.
[15] I. Du Rand,et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease , 2020, Thorax.
[16] A. Nanzer,et al. Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[17] C. Jenkins,et al. Mepolizumab effectiveness and identification of super-responders in severe asthma , 2020, European Respiratory Journal.
[18] K. Sladek,et al. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.
[19] I. Pavord,et al. An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.
[20] P. Gibson,et al. Targeting treatable traits in severe asthma: a randomised controlled trial , 2019, European Respiratory Journal.
[21] S. Hiles,et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis , 2019, European Respiratory Journal.
[22] M. Cabana,et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline , 2019, European Respiratory Journal.
[23] M. Nawijn,et al. A review on the pathophysiology of asthma remission. , 2019, Pharmacology & therapeutics.
[24] D. Aletaha,et al. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. , 2019, Rheumatology.
[25] C. Jenkins,et al. A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. , 2019, The Journal of allergy and clinical immunology.
[26] H. Ortega,et al. Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.
[27] W. Busse. Biological treatments for severe asthma: A major advance in asthma care. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[28] I. Pavord,et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report , 2019, European Respiratory Journal.
[29] J. Krings,et al. Role of Biologics in Asthma , 2019, American journal of respiratory and critical care medicine.
[30] W. Busse,et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. , 2019, The journal of allergy and clinical immunology. In practice.
[31] C. Jenkins,et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations , 2018, Respirology.
[32] C. Bai,et al. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema , 2018, Respiration.
[33] Y. Bossé,et al. Novel genes and insights in complete asthma remission: A genome‐wide association study on clinical and complete asthma remission , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[34] T. Sigsgaard,et al. Determinants of persistent asthma in young adults , 2018, European clinical respiratory journal.
[35] K. Sladek,et al. Influence of omalizumab therapy on airway remodeling assessed with high-resolution computed tomography (HRCT) in severe allergic asthma patients. , 2015, Advances in respiratory medicine.
[36] E. Bel,et al. Clinical predictors of remission and persistence of adult‐onset asthma , 2018, The Journal of allergy and clinical immunology.
[37] E. Israel,et al. Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.
[38] C. Jenkins,et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[39] T. Huizinga,et al. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations , 2017, Therapeutic advances in musculoskeletal disease.
[40] D. Postma,et al. Childhood factors associated with complete and clinical asthma remission at 25 and 49 years , 2017, European Respiratory Journal.
[41] P. Emery,et al. Modifying the trajectory of asthma—are there lessons from the use of biologics in rheumatology? , 2017, The Lancet.
[42] G. Canonica,et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months , 2017, Clinical and Translational Allergy.
[43] K. Rabe,et al. Asthma transition from childhood into adulthood. , 2017, The Lancet. Respiratory medicine.
[44] P. O'Byrne,et al. Biologics and the lung: TSLP and other epithelial cell‐derived cytokines in asthma , 2017, Pharmacology & therapeutics.
[45] C. Wagner,et al. Airway remodeling in asthma: what really matters , 2017, Cell and Tissue Research.
[46] O. Niemelä,et al. A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. , 2016, Respiratory medicine.
[47] I. Pavord,et al. Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.
[48] R. de Marco,et al. Seventy Years of Asthma in Italy: Age, Period and Cohort Effects on Incidence and Remission of Self-Reported Asthma from 1940 to 2010 , 2015, PloS one.
[49] M. Tamm,et al. Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab , 2015, PloS one.
[50] D. Mungan,et al. Prognosis of adult asthma: a 7-year follow-up study. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[51] G. Canonica,et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. , 2014, Immunology letters.
[52] P. Gibson,et al. Full blood count parameters for the detection of asthma inflammatory phenotypes , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[53] C. Robertson,et al. Outcomes of childhood asthma to the age of 50 years. , 2014, The Journal of allergy and clinical immunology.
[54] M. Bugiani,et al. The Course of Asthma in Young Adults: A Population-Based Nine-Year Follow-Up on Asthma Remission and Control , 2014, PloS one.
[55] M. Chan-yeung,et al. Sustained Elevation of Systemic Oxidative Stress and Inflammation in Exacerbation and Remission of Asthma , 2013, ISRN allergy.
[56] D. Serisier. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. , 2013, The Lancet. Respiratory medicine.
[57] R. Luukkonen,et al. Positive Exercise Test and Obstructive Spirometry in Young Male Conscripts Associated with Persistent Asthma 20 years Later , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.
[58] G. Canonica,et al. Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients , 2012, International journal of immunopathology and pharmacology.
[59] M. Hoshino,et al. Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma , 2012, Respiration.
[60] L. Boulet,et al. Airway function, inflammation and regulatory T cell function in subjects in asthma remission. , 2012, Canadian respiratory journal.
[61] Margaret W Leigh,et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.
[62] A. James,et al. Remission of asthma: The next therapeutic frontier? , 2011, Pharmacology & therapeutics.
[63] D. Postma,et al. Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. , 2011, American journal of respiratory and critical care medicine.
[64] P. Gibson,et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. , 2011, Age and ageing.
[65] D. Postma,et al. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV(1). , 2010, Respiratory medicine.
[66] K. Bønnelykke,et al. Long-term studies of the natural history of asthma in childhood. , 2010, The Journal of allergy and clinical immunology.
[67] Y. Goekoop-Ruiterman,et al. Rheumatoid arthritis: Can we achieve true drug-free remission in patients with RA? , 2010, Nature Reviews Rheumatology.
[68] H. Mochizuki,et al. Relationship between bronchial hyperreactivity and asthma remission during adolescence. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[69] L. Boulet. Influence of comorbid conditions on asthma , 2009, European Respiratory Journal.
[70] S. Dahlén,et al. No further increase of incidence of asthma: incidence, remission and relapse of adult asthma in Sweden. , 2008, Respiratory medicine.
[71] P. J. Barnes,et al. Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.
[72] A. Lindberg,et al. Outcome and severity of adult onset asthma--report from the obstructive lung disease in northern Sweden studies (OLIN). , 2007, Respiratory medicine.
[73] L. Irving,et al. The natural history of asthma from childhood to adulthood , 2007, International journal of clinical practice.
[74] T. Gislason,et al. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study) , 2007, European Respiratory Journal.
[75] John W. Wilson,et al. Airway remodelling in asthma: current understanding and implications for future therapies. , 2006, Pharmacology & therapeutics.
[76] Deborah Jarvis,et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. , 2006, The Journal of allergy and clinical immunology.
[77] H. Bisgaard,et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. , 2006, The New England journal of medicine.
[78] Vernon M Chinchilli,et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.
[79] H. Hoogsteden,et al. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. , 2005, Respiratory medicine.
[80] Klas Svensson,et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.
[81] D. Postma,et al. Childhood factors associated with asthma remission after 30 year follow up , 2004, Thorax.
[82] Philip Marcus,et al. Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.
[83] Phil A. Silva,et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. , 2003, The New England journal of medicine.
[84] H. Hoogsteden,et al. Asthma remission: does it exist? , 2003, Current opinion in pulmonary medicine.
[85] A. Bush,et al. Early thickening of the reticular basement membrane in children with difficult asthma. , 2003, American journal of respiratory and critical care medicine.
[86] P. Phelan,et al. The Melbourne Asthma Study: 1964-1999. , 2002, The Journal of allergy and clinical immunology.
[87] P. Barnes,et al. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.
[88] H. Hoogsteden,et al. Airway inflammation is present during clinical remission of atopic asthma. , 2001, American journal of respiratory and critical care medicine.
[89] J Bousquet,et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. , 2000, American journal of respiratory and critical care medicine.
[90] H. Hoogsteden,et al. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. , 2000, American journal of respiratory and critical care medicine.
[91] E. Rönmark,et al. Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study , 1999, Thorax.
[92] H. Maruo. [The relapse rate in patients with bronchial asthma remission and the risk factors of relapse]. , 1999, Arerugi = [Allergy].
[93] G. Crompton,et al. Management of Severe Asthma , 1998 .
[94] P. Emery,et al. Early rheumatoid arthritis: time to aim for remission? , 1995, Annals of the rheumatic diseases.
[95] L. Boulet,et al. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. , 1994, Chest.
[96] P D Phelan,et al. The natural history of childhood asthma to adult life. , 1980, British medical journal.